The constraint is unclear. Go inside the system.
When growth is real but the reason it is not becoming repeatable is still ambiguous, an external read is not enough. The Diagnostic Sprint works inside the system — across evidence, decisions and operating reality — to identify what is actually constraining scale and what deserves attention next.
Four weeks · €6,000 · no prior Session required.
Use the Sprint when the answer cannot be responsibly inferred from the outside.
Cross-dimensional signals
Technology, organisation, trust, delivery or market symptoms are interacting and it is not clear which one is actually limiting the system.
Internal evidence required
The answer depends on architecture, decision rights, delivery patterns, customer evidence or operating data that cannot be understood from an external conversation alone.
Repeated scaling failure
Pilots work, customers are real or growth is visible — but the same friction returns across integrations, teams, deployments or commitments.
A consequential decision
The next move — product, platform, organisation, deployment, investment or partner strategy — is material enough that acting on assumptions would be expensive.
If the situation is already bounded, do not manufacture a diagnostic project. Start with the smallest engagement that can answer the decision.
The Scaling Readiness Check is optional. If already completed, it can be used as one input into the Sprint.
Three maturity dimensions. Six investigative lenses.
The Scaling System Maturity Framework provides the three-dimensional maturity backbone: Technology, Organisation and Trust. The Sprint then uses the six CompoundWorks capabilities as investigation lenses to understand where the constraint is actually forming and what decision it affects.
System Diagnosis & Scale Readiness
What is actually constraining repeatable growth, and what is likely to break next?
Product Strategy, Positioning & Roadmap
Is the company building the right product boundary, wedge and roadmap for the market it is trying to own?
Product, Platform & System Architecture
Can the architecture absorb more customers, integrations, deployment contexts and product complexity without redesign?
Organisation, Decision & Delivery Architecture
Can authority, ownership and delivery hold under pressure without founder routing or heroic coordination?
Trust, Assurance & Deployment Readiness
Can customers, procurement, regulators and internal teams rely on the system through evidence rather than personal confidence?
Market, Partner & Deployment Scaling
Can the company reproduce adoption through customers, partners and deployment paths instead of restarting from zero each time?
The Sprint does not force equal depth across all six. Evidence determines where the investigation goes deeper.
Establish the decision context
Align on the decision in front of the company, the symptoms already visible and the evidence needed to distinguish causes from effects. Existing material is reviewed before interviews begin.
Read the system from inside
Review the relevant architecture, product, delivery, organisational, customer and trust evidence. Interview the people closest to the decisions and hand-offs that matter.
Separate symptoms from the limiting structure
Use the SSMF and the six capabilities to test competing hypotheses, identify maturity mismatches and determine where pressure is actually accumulating.
Turn diagnosis into an executive decision
Consolidate the evidence into a clear read on the likely binding constraint or coupled constraints, the risks around them, what is likely to break next and the smallest set of decisions that can materially improve scale-readiness.
Selective internal access
Relevant leaders, working evidence and system context — enough to test the constraint, not an open-ended discovery exercise.
- Product roadmap
- Architecture / integration material
- Delivery and escalation patterns
- Organisation and decision ownership
- Customer / deployment evidence
- Assurance / procurement evidence
- Partner model
- Investment / growth assumptions
Scope follows the decision and the hypotheses being tested.
Evidence for the decision — not a generic transformation report.
- The likely binding constraintAn evidence-based view of the structure most likely limiting repeatable scale, including coupled constraints where the evidence does not support a single answer.
- The maturity profileA three-dimensional SSMF read across Technology, Organisation and Trust, with the relevant capability evidence behind it.
- What breaks nextThe failure modes most likely to surface if the current growth thesis is pursued without structural change.
- The decision agendaA prioritised set of decisions, experiments or focused interventions — including where no intervention is warranted yet.
Investment Readiness Diagnostic
When the immediate decision is a funding round, the same four-week diagnostic can be weighted toward the growth thesis an investor will test: product and platform scalability, organisational key-person risk, deployment readiness, evidence of repeatability, market and partner scaling, and what is likely to break under the next stage of growth.
The SSMF remains the three-dimensional maturity backbone. The six capabilities shape the evidence review; they do not become six maturity scores.
Commissioned by the company or founders before a funding round. This is distinct from Scale-Readiness Diligence, which is independent transaction assessment commissioned by investors or acquirers. See the investor and M&A perspective →
Use the smallest engagement that can answer the decision.
The Diagnostic Sprint is a starting point when ambiguity is the problem — not a prerequisite when clarity already exists.
The diagnosis should reduce work, not create more of it.
Act internally
The evidence is clear enough for the leadership team to act without additional CompoundWorks involvement.
Start a focused engagement
The constraint is sufficiently bounded and a specific intervention is justified — product, architecture, organisation, trust, deployment or market scaling. See focused engagements →
Continue with strategic support
The decision is clear but execution spans time, teams or repeated leadership choices. Strategic Advisory or Embedded Scaling Leadership may then be appropriate.
If an Executive Diagnostic Session directly precedes the Sprint, its €950 fee is credited in full. If the problem and decision are already clear enough, start directly with the relevant engagement. The Sprint ends when the decision is clear enough to act. Any implementation work is scoped separately and only where it adds value.
Find the constraint before you scale around it.
If the symptoms are visible but the real limiting structure is still unclear, the Diagnostic Sprint is designed to turn ambiguity into an evidence-based decision.